Evaxion Biotech A/S (EVAX) Research

Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.

Market snapshot

Symbol
EVAX
Price
$3.05
Day change
-8.13%
Market cap
$19.3M
P/E ratio
-2.61x
52-week range
2.19-12.15
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$9.50

Peer companies

  • Annovis Bio, Inc. (ANVS)
  • BioAtla, Inc. (BCAB)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Celularity Inc. (CELU)
  • Generation Bio Co. (GBIO)
  • Mural Oncology plc (MURA)
  • PolyPid Ltd. (PYPD)
  • Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Recent insider activity

  • Bitsch-Norhave Jens — trade (0 shares) on 2026-04-16
  • Mattsson Andreas Holm — trade (0 shares) on 2026-03-18
  • Mattsson Andreas Holm — trade (0 shares) on 2026-03-18
  • Mattsson Andreas Holm — trade (35000 shares) on 2022-01-01
  • Mattsson Andreas Holm — trade (645700 shares) on 2025-01-31

Open Evaxion Biotech A/S (EVAX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.